Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Amgen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Blueprint Medicines Corporation, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exact Sciences Corporation, Jazz Pharmaceuticals, Inc., Lilly USA, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., and Takeda Oncology.

Community Practice Connections™: 22nd Annual International Lung Cancer Congress®

Release Date: October 29, 2021
Expiration Date: October 29, 2022

Activity Overview

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 22nd Annual International Lung Cancer Congress®  held in July 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with lung cancer and putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Blueprint Medicines Corporation, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exact Sciences Corporation, Jazz Pharmaceuticals, Inc., Lilly USA, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Regeneron Pharmaceuticals, Inc., and Takeda Oncology.

 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess biomarkers and testing strategies to optimize selection of therapy in patients with thoracic malignancies
  • Describe emerging evidence concerning the management of patients with nonmetastatic lung cancer
  • Integrate recent clinical data on single-agent and combination immunotherapeutic approaches to care for patients with advanced thoracic malignancies
  • Evaluate recent data sets on targeted and cytotoxic strategies for the management of patients with thoracic malignancies
  • Outline optimal and personalized strategies for sequencing therapy utilizing clinical trial evidence, performance status, and tumor characteristics
  • Identify approaches to address variances in care for patients with thoracic malignancies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities
 

Faculty

David R. Gandara, MD
David R. Gandara, MD
Professor of Medicine Emeritus
Division of Hematology/Oncology
Director of Thoracic Oncology
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosures: Grant research support: Amgen, AstraZeneca, Genentech, Merck & Co; Consultant: AstraZeneca (institutional), Eli Lilly and Company, Guardant Health (institutional), Hoffmann-La Roche/Genentech (institutional), lnivata, 10 Biotech (institutional), Merck & Co, Novartis Pharmaceuticals, Oncocyte (institutional).

Marina Garassino, MD
Marina Garassino, MD
Head, Simple Structure of Toraco
Pulmonary Medical Oncology
IRCCS National Cancer Institute
Milan, Italy

Disclosures: Grant research support: AIRC, Italian Medicines Agency AIFA; Consultant: AstraZeneca, Roche, Bristol Myers Squibb, Sanofi, Mirati Therapeutics, Daiichi Sankyo, Merck & Co, Pfizer, Lilly, Takeda, Janssen; Speakers bureau: Merck & Co.

Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research, Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosures: Grant research support: AstraZeneca, Eli Lilly and Company, Genentech/Hoffmann-La Roche, Merck & Co; Consultant: AbbVie, ARMO Biosciences, AstraZeneca, Bayer Healthcare Pharmaceuticals, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, eFFECTOR Therapeutics, Eli Lilly and Company, EMD Serono, Foundation Medicine, Genentech/Hoffmann-La Roche, Genmab, Gilead Sciences, Halozyme, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck & Co, Mirati Therapeutics, Nektar Therapeutics, Neon Therapeutics, NextCure, Novartis Pharmaceuticals, Ocean Biomedical, Oncternal Therapeutics, Pfizer, Refactor Health, Ribon Therapeutics, Sanofi, Seattle Genetics, Shire Pharmaceuticals, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Symphogen, Takeda Pharmaceutical Company, Tesaro, Tocagen, Ventana Medical Systems, WindMIL Therapeutics; Other: Board Member (non-executive/ independent): Immunocore Holdings Limited, Junshi Biosciences

Heather A. Wakelee, MD
Heather A. Wakelee, MD
Professor of Medicine
Chief, Division of Oncology
Stanford University School of Medicine
Deputy Director, Stanford Cancer Institute
Stanford, CA

Disclosures: Grant research support: ACEA Biosciences, Arrys Therapeutics, AstraZeneca/MedImmune, Bristol Myers Squibb, Celgene, Clovis Oncology, Genentech/Roche, Merck, Novartis, Pharmacyclics, Seagen, Xcovery; Consultant: Paid consultant: AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Helsinn, Mirati, Unpaid consultant: Genentech/Roche, Merck; Other: Steering committee participation/unpaid adviser: Cellworks, Genentech/Roche, Merck, Takeda

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By